{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T23:40:16Z","timestamp":1773618016494,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to assess DPP4i-induced bullous pemphigoid among our BP patients and characterize the clinical, laboratory and histological features of this drug-induced disease form. In our patient cohort, out of 127 BP patients (79 females (62.2%), 48 males (37.7%)), 14 (9 females and 5 males) were treated with DPP4i at the time of BP diagnosis. The Bullous Pemphigoid Disease Area Index (BPDAI) urticaria\/erythema score was significantly lower, and the BPDAI damage score was significantly higher in DPP4i-BP patients compared to the nonDPP4i group. Both the mean absolute eosinophil number and the mean periblister eosinophil number was significantly lower in DPP4i-BP patients than in nonDPP4i cases (317.7 \u00b1 0.204 vs. 894.0 \u00b1 1.171 cells\/\u03bcL, p &lt; 0.0001; 6.75 \u00b1 1.72 vs. 19.09 \u00b1 3.1, p = 0.0012, respectively). Our results provide further evidence that DPP4i-associated BP differs significantly from classical BP, and presents with less distributed skin symptoms, mild erythema, normal or slightly elevated peripheral eosinophil count, and lower titers of BP180 autoantibodies. To our knowledge, this is the first case series of DPP4i-related BP with a non-inflammatory phenotype in European patients.<\/jats:p>","DOI":"10.3390\/jcm10091916","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:41:58Z","timestamp":1619606518000},"page":"1916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid"],"prefix":"10.3390","volume":"10","author":[{"given":"\u00c1gnes","family":"Kiny\u00f3","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Hanyecz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalma","family":"V\u00e1rszegi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-8846","authenticated-orcid":false,"given":"Csaba","family":"Gy\u00f6m\u00f6rei","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endre","family":"K\u00e1lm\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00edmea","family":"Berki","sequence":"additional","affiliation":[{"name":"Department of Immunology and Biotechnology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolland","family":"Gyulai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Oncodermatology, University of P\u00e9cs Medical School Clinical Centre, H7632 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jid.2017.01.028","article-title":"Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016","volume":"137","author":"Schmidt","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: A review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014Incidence and mortality in the UK: Population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"Recke","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.13189","article-title":"Increasing incidence of bullous pemphigoid in Northern Finland: A retrospective database study in Oulu University Hospital","volume":"171","author":"Jokelainen","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1111\/jdv.14957","article-title":"Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors","volume":"32","author":"Gravani","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.14649","article-title":"Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade","volume":"32","author":"Fania","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/jdi.12877","article-title":"Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9304 diabetes mellitus patients","volume":"10","author":"Kawaguchi","year":"2019","journal-title":"J. Diabetes. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1111\/jdv.14965","article-title":"Commentary on \u2018Changing prevalence of diabetes mellitus in bullous pemphigoid: It is the dipeptidyl peptidase-4 inhibitors\u2019","volume":"32","author":"Fania","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Aranburu","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: A case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"Moulis","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","article-title":"Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology"},{"key":"ref_19","unstructured":"Kridin, K., and Cohen, A.D. (2018). Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis. J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: A report of three cases","volume":"29","author":"Jacobsoone","year":"2015","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1684\/ejd.2018.3371","article-title":"Bullous pemphigoid in patients with DDP-4 inhibitors at the onset of disease: Does this differ from common bullous pemphigoid?","volume":"28","author":"Patsatsi","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of Dipeptidyl Peptidase 4 Inhibitor Use with Risk of Bullous Pemphigoid in Patients with Diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients with Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase IV inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.16656","article-title":"Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: A report of three patients","volume":"179","author":"Mai","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","article-title":"Clinical and Immunological Profiles of 14 Patients with Bullous Pemphigoid without IgG Autoantibodies to the BP180 NC16A Domain","volume":"154","author":"Nakama","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ijd.14005","article-title":"Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization","volume":"57","author":"Ishii","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: Prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish Nationwide Registry Study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.dsx.2020.03.001","article-title":"Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases","volume":"14","author":"Jha","year":"2020","journal-title":"Diabetes Metab. Syndr"},{"key":"ref_37","first-page":"249","article-title":"Association between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study","volume":"111","year":"2020","journal-title":"Actas Dermosifiliogr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous Pemphigoid Associated with Linagliptin Treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e001765","DOI":"10.1136\/bmjdrc-2020-001765","article-title":"Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and\/or dipeptidyl peptidase-4 inhibitor: A nationwide study","volume":"9","author":"Rokszin","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/25785826.2019.1619233","article-title":"Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: A recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics","volume":"42","author":"Nishie","year":"2019","journal-title":"Immunol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3325\/cmj.2020.61.93","article-title":"The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: A retrospective study","volume":"61","year":"2020","journal-title":"Croat. Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e13790","DOI":"10.1111\/dth.13790","article-title":"Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences","volume":"33","author":"Kridin","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0190-9622(87)80227-X","article-title":"Blood eosinophilia as a severity marker for bullous pemphigoid","volume":"16","author":"Bernard","year":"1987","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Messingham, K.N., Holahan, H.M., Frydman, A.S., Fullenkamp, C., Srikantha, R., and Fairley, J.A. (2014). Human eosinophils express the high affinity IgE receptor, Fc\u03b5RI, in bullous pemphigoid. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107725"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","article-title":"Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"78","author":"Fania","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2340\/00015555-3010","article-title":"Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading","volume":"98","author":"Takama","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/bjd.17690","article-title":"Epitope spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"180","author":"Iranzo","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40257-020-00563-7","article-title":"More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study","volume":"22","author":"Schmidt","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4\/CD26 in Bullous Pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI3335","article-title":"Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls","volume":"102","author":"Borradori","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor","volume":"13","author":"Kaczowka","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_56","first-page":"386","article-title":"DPP4 in Diabetes","volume":"6","author":"Wronkowitz","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: A review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo","volume":"181","author":"Forssmann","year":"2008","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin Plays a Role in the In Vitro. Generation of the Linear IgA Dermatosis Antigen LADB97","volume":"129","author":"Hofmann","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2249.2004.02401.x","article-title":"Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes","volume":"135","author":"Schmidt","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.4049\/jimmunol.1001524","article-title":"Ectodomain shedding generates Neoepitopes on collagen XVII, the major autoantigen for bullous pemphigoid","volume":"185","author":"Nishie","year":"2010","journal-title":"J. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/9\/1916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:54:43Z","timestamp":1760162083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/9\/1916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["jcm10091916"],"URL":"https:\/\/doi.org\/10.3390\/jcm10091916","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}